Wegovy API — Separating the Search Term from the Real Clinical Picture

The biggest misconception: "Wegovy API" is not a patient-facing tool

"API" in pharmacy and healthcare IT usually means an application programming interface, the kind of connection that lets one software system talk to another. In that context, pharmaceutical companies do publish technical data feeds for clinical systems and electronic prescribing platforms, but none of these are consumer-facing, and none of them change what a patient needs to do to obtain Wegovy.

The misconception worth correcting here is the idea that there is a shortcut, a digital system you can tap into to get Wegovy delivered without the clinical steps. There isn't. Wegovy is a Prescription-Only Medicine under the Human Medicines Regulations 2012, which means a registered prescriber must assess your suitability before any supply can be made. That is not a bureaucratic hurdle; it is the process that keeps the medicine safe for the person taking it. A real clinical review, carried out by a person who can read your medical history and ask follow-up questions, is the mechanism that catches contraindications, flags interactions, and sets the right starting dose.

If you arrived here because a tech article or social media post used the phrase, it is worth knowing the term has no settled meaning in the UK weight-loss context. What matters for anyone considering Wegovy is what happens during a proper clinical consultation, and that is what the sections below address.

How semaglutide's biological "mechanism" actually works

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after eating; it signals to the brain that you are full, slows the rate at which the stomach empties, and reduces the drive to eat. Semaglutide mimics that signal in a sustained way, the weekly injection keeps GLP-1 receptor activity elevated throughout the week rather than for the short window after a meal.

The practical result, documented in the STEP 1 trial published in the New England Journal of Medicine, was an average body-weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose, compared with about 2.4% on placebo, in adults with obesity and no type 2 diabetes. The MHRA subsequently approved a higher 7.2 mg maintenance dose; a dedicated single-dose pen for that strength was cleared on 14 April 2026. Trials at 7.2 mg reported average losses of around 20.7% over 72 weeks, approaching the results seen with tirzepatide. You can read the NHS's patient-level explanation of how semaglutide works on the NHS semaglutide medicines page.

None of this is visible in any software interface. The biology operates through receptors in your gut and brain, and the clinical process that sits around it (prescriber assessment, dose titration, monitoring) operates through qualified human oversight. If you want a closer look at the patient information for Wegovy, that page covers the full prescribing detail in one place. For more background on semaglutide as a treatment, the semaglutide overview on this site covers the licensing and evidence in detail.

What a legitimate clinical pathway for Wegovy looks like in practice

Accessing Wegovy legally in the UK means one thing: a prescription, issued by a registered prescriber who has reviewed your health information. The route divides into NHS and private. On the NHS, Wegovy is available through specialist weight management services under NICE's technology appraisal TA875, which sets specific criteria, including a BMI of 35 or above, at least one weight-related comorbidity, and treatment within a multidisciplinary service, for a maximum of two years. Waiting lists for those services are commonly long.

Private prescribing follows the licensed eligibility criteria set out in the medicine's UK Summary of Product Characteristics: adults with a BMI of 30 or above, or 27–29.9 with a qualifying weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI figure alone does not determine suitability, the prescriber weighs the full clinical picture. Treatment begins at a lower dose, and if you want to understand how that works in practice, the Wegovy 1 page explains the initial dose stage in detail, while the Wegovy 2 page covers what to expect as your dose increases.

At nume, every consultation is read and assessed by a GPhC-registered Independent Prescriber, not an automated scoring system. Photo-ID verification, live weight confirmation, and a review of any existing treatments are part of the process. If clinically suitable and the order is placed before 12pm Monday to Friday, treatment is dispatched the same day and arrives free the next working day via DPD tracked delivery. Alongside clinical support, the Wegovy app is there to help you track your progress and stay on top of your treatment between consultations. For a full picture of what is included, the Wegovy treatment page sets out the detail. If you are still deciding which treatment might fit your situation, the weight-loss treatments overview is a useful starting point.

One practical habit worth building before using any online pharmacy: spend sixty seconds on the GPhC register at pharmacyregulation.org/registers and confirm the pharmacy's registration is current. It is a free check that takes less time than reading most product pages, and it is the single clearest signal that a service is operating within UK law. You can verify nume's GPhC premises registration (number 9012878) there directly.

If you have questions about the consultation process or want to talk through whether Wegovy is likely to be suitable for you, the frequently asked questions page covers the most common queries, and the contact page connects you with the aftercare team. When you're ready to take the next step, start your free consultation and a prescriber will review your information the same day.